Opthea's Phase 1 Data From Wet AMD Clinical Trial Presented at EURETINA Congress 2016
September 12, 2016 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Sep 12, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY), a developer of novel biologic therapies for the treatment of eye diseases, today announced that data...
Opthea Reports Positive Data From Wet AMD Clinical Trial
July 25, 2016 19:15 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Jul 25, 2016) - Opthea Limited (ASX: OPT)
Phase 1 dose escalation study met primary objective demonstrating OPT-302 safety and...
Opthea to Host Conference Call Providing Update on Phase 1 Wet AMD Clinical Trial With OPT-302
July 25, 2016 02:15 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Jul 25, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY), a developer of novel biologic therapies for the treatment of eye diseases, will host a conference call...
Opthea Doses First Patient in Phase 2A Dose Expansion Study for OPT-302 in Wet AMD
May 05, 2016 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - May 5, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY)
Phase 2A dose expansion follows successful completion of the 28 day safety...
Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective
April 21, 2016 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Apr 21, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY)
OPT-302 safe and well tolerated as monotherapy and in combination with...